Standardized Diagnosis and Treatment of Endocrine Hypertension

Overview

Cases of endocrine hypertension or primary hypertension who have signed informed consent will be collected. Patients with endocrine hypertension will be divided into surgical treatment group and drug treatment group according to actual treatment situation. A database will be established for all patients. The investigators will comprehensively evaluate the general conditions, past medical history, metabolic and biochemical indicators, psychological status, cardiovascular risk factors. All the patients will be followed up for 12 months at baseline, 6 months and 12 months. Clinical data and specimen will be collected.

The investigators will collect 100 patients with secretory hypertension and 100 patients with essential hypertension. Patients with endocrine hypertension will be divided into surgical treatment group and drug treatment group according to actual treatment situation. Resected specimens from surgical patients will be used for immunohistochemistry and western blot. A database will be established for all patients to assess their general situation, past medical history, metabolic and biochemical indicators, psychological status, cardiovascular risk factors, etc. The investigators expect to find more accurate screening indicators from blood and urine specimens. All the patients will be followed up for 12 months at baseline, 6 months and 12 months. Blood pressure, degree of atherosclerosis, biochemical markers, hormone levels and cardiac function indicators will be measured at three time points.

Conditions

Interventions